Patent US4882347A successfully refreshed from Google Patents.
US4882347A
Expired / Lapsed
US
⏱️ 0.0 years remaining
"N-imidazolyl derivatives of bicyclic compounds and pharmaceutical compositions containing the same"
Assignee: Pfizer Italia SRL
•
Filing: 1988-06-02
•
Granted: 1989-11-21
•
Expires: 2008-06-02
Abstract
Abstract A pharmaceutical compositon having activity against nephropathies comprising, as an active agent, a therapeutically effective amount of a compound of formula (I) <IMAGE> (I) wherein (a) <IMAGE> wherein Y completes a single bond or is oxygen or a -CH2- group and the symbol <IMAGE> represents a single bond or (b) <IMAGE> <IMAGE> and the symbol <IMAGE> represents a double bond; one of R1, R2, R3 and R4 is -CH2OH, C2-C4 acyl, <IMAGE> <IMAGE> in which each of R1, R8 and R9 is independently hydrogen or C1-C4 alkyl and the others are independently chosen from hydrogen, hydroxy, halogen, C1-C4 alkyl, C1-C4 alkoxy and -COOR, wherein R7 is as defined above, and one of R5 and R6 is hydrogen and the other is hydrogen, C1-C6 alkyl or phenyl; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier and/or diluent.
Inventors
- 👤 Paolo Cozzi
- 👤 Corrado Ferti
- 👤 Patricia Salvati
- 👤 Germano Carganico
- 👤 Antonio Pillan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 18:18
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61P; A61P13/00; A61P13/02; A61P15/00; C; C07; C07D; C07D233/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
236 words
A method of treating nephropathies in mammals, said nephropathies being selected from the group consisting of glumerulonephritis, nephropathy secondary to lupus erithematosus, and hyperlipidaemias secondary to nephrotic syndrome, which comprises administering to said mammals an effective amount of a pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound of the formula (I): ##STR23## wherein (I) --Z-- is: ##STR24## wherein Y completes a single bond or is oxygen or a --CH 2 -- group and the symbol: ##STR25## represents a single or a double bond, or (II) --Z-- is: ##STR26## and the symbol: ##STR27## represents a double bond; one of R 1 , R 2 , R 3 , R 4 is --CH 2 OH, C 2 -C 4 acyl, --CONR 7 R 8 , --COOR 7 , --CH 2 --COOR 7 , --CH 2 CONR 7 R 8 , --CH═C(R 7 )--COOR 8 or --CH═C(R 9 )--CONR 7 R 8 in which each of R 7 , R 8 and R 9 is independently hydrogen or C 1 -C 4 alkyl and the others are independently selected from the group consisting of hydrogen, hydroxy, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy and --COOR 7 , wherein R 7 is as defined above, and one of R 5 and R 6 is hydrogen and the other is hydrogen, C 1 -C 6 alkyl or phenyl; and (b) a pharmaceutically acceptable carrier.
Claim 2
Independent Claim
236 words
A method of treating nephropathies in mammals, said nephropathies being selected from the group consisting of glumerulonephritis, nephropathy secondary to lupus erithematosus, and hyperlipidaemias secondary to nephrotic syndrome, which comprises administering to said mammals an effective amount of a pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound of the formula (I): ##STR23## wherein (I) --Z-- is: ##STR24## wherein Y completes a single bond or is oxygen or a --CH 2 -- group and the symbol: ##STR25## represents a single or a double bond, or (II) --Z-- is: ##STR26## and the symbol: ##STR27## represents a double bond; one of R 1 , R 2 , R 3 , R 4 is --CH 2 OH, C 2 -C 4 acyl, --CONR 7 R 8 , --COOR 7 , --CH 2 --COOR 7 , --CH 2 CONR 7 R 8 , --CH═C(R 7 )--COOR 8 or --CH═C(R 9 )--CONR 7 R 8 in which each of R 7 , R 8 and R 9 is independently hydrogen or C 1 -C 4 alkyl and the others are independently selected from the group consisting of hydrogen, hydroxy, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy and --COOR 7 , wherein R 7 is as defined above, and one of R 5 and R 6 is hydrogen and the other is hydrogen, C 1 -C 6 alkyl or phenyl; and (b) a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
101 words
The method of claim 1, wherein in the compound of formula (I): --Z-- is ##STR28## one of R 1 , R 2 , R 3 and R 4 is --CH 2 OH, C 2 -C 4 acyl, --CONR 7 R 8 , --COOR 7 , --CH 2 --COOR 7 , --CH 2 --CONR 7 R 8 , --CH--C(R 7 )--COOR 8 or --CH═C(R 9 )COONR 7 R 8 , in which R 7 , R 8 and R 9 is independently hydrogen or C 1 -C 4 alkyl and the others are hydrogen, and R 5 and R 6 are hydrogen.
Claim 4
Dependent Claim
13 words
The method of claim 1, wherein said compound of formula (I) is 1,2-dihydro-3-(1-imidazolyl)-6-carboxynaphthalene.
Claim 5
Dependent Claim
29 words
The method of claim 1, wherein said compound of the formula (I) is selected from the group consisting of: 1,2-dihydro-3-(1-imidazolyl)-6-ethoxycarbonylnaphthalene; 1,2-dihydro-3-(1-imidazolyl)-6-hydroxymethylnaphthalene; 1,2-dihydro-3-(1-imidazolyl)-7-carboxynaphthalene; 1,2-dihydro-3-(1-imidazolyl)-6-(2-carboxyvinyl)-naphthalene; 1,2-dihydro-3-(1-imidazolyl)-6-(2-ethoxycarbonylvinyl)naphthalene; 1,2-dihydro-3-(1-imidazolyl)-6-carboxymethylnaphthalene; 1,2,3,4-tetrahydro-2-(1-imidazolyl)-7-carboxynaphthalene; 2-(1-imidazolyl)-7-carboxynaphthalene; and 2-(1-imidazolyl)-6-carboxynaphthalene.
Claim 6
Dependent Claim
24 words
The method of claim 1, wherein said hyperlipidaemias secondary to nephrotic syndrome are hypercholesterolaemia secondary to nephrotic syndrome and hypertriglyceridaemia secondary to nephrotic syndrome.
References Cited (Backward Citations)
US3992403A
Cited
FR2510113A1
Cited
US4492707A
Cited
US4588738A
Cited
US4510149A
Cited
US4602022A
Cited
GB2141705A
Cited
US4634705A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-20 | 1993-05-22 | 1993-11-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-20 | 1997-05-22 | 1997-11-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-20 | 2001-05-22 | 2001-11-21 | $7700.00 | Window Closed / Lapsed |